FR2888507B1 - USE OF SERTRALINE IN COMBINATION WITH ALKALOID FOR THE TREATMENT OF CANCER - Google Patents

USE OF SERTRALINE IN COMBINATION WITH ALKALOID FOR THE TREATMENT OF CANCER

Info

Publication number
FR2888507B1
FR2888507B1 FR0507481A FR0507481A FR2888507B1 FR 2888507 B1 FR2888507 B1 FR 2888507B1 FR 0507481 A FR0507481 A FR 0507481A FR 0507481 A FR0507481 A FR 0507481A FR 2888507 B1 FR2888507 B1 FR 2888507B1
Authority
FR
France
Prior art keywords
sertraline
alkaloid
cancer
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0507481A
Other languages
French (fr)
Other versions
FR2888507A1 (en
Inventor
Frederic Revah
Marius Tuynder
Robert Amson
Adam Telerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abionyx Pharma SA
Original Assignee
Cerenis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerenis SA filed Critical Cerenis SA
Priority to FR0507481A priority Critical patent/FR2888507B1/en
Priority to PCT/EP2006/064159 priority patent/WO2007006799A1/en
Publication of FR2888507A1 publication Critical patent/FR2888507A1/en
Application granted granted Critical
Publication of FR2888507B1 publication Critical patent/FR2888507B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0507481A 2005-07-12 2005-07-12 USE OF SERTRALINE IN COMBINATION WITH ALKALOID FOR THE TREATMENT OF CANCER Expired - Fee Related FR2888507B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0507481A FR2888507B1 (en) 2005-07-12 2005-07-12 USE OF SERTRALINE IN COMBINATION WITH ALKALOID FOR THE TREATMENT OF CANCER
PCT/EP2006/064159 WO2007006799A1 (en) 2005-07-12 2006-07-12 Use of sertraline in combination with an alkaloid for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507481A FR2888507B1 (en) 2005-07-12 2005-07-12 USE OF SERTRALINE IN COMBINATION WITH ALKALOID FOR THE TREATMENT OF CANCER

Publications (2)

Publication Number Publication Date
FR2888507A1 FR2888507A1 (en) 2007-01-19
FR2888507B1 true FR2888507B1 (en) 2007-10-05

Family

ID=35840562

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0507481A Expired - Fee Related FR2888507B1 (en) 2005-07-12 2005-07-12 USE OF SERTRALINE IN COMBINATION WITH ALKALOID FOR THE TREATMENT OF CANCER

Country Status (2)

Country Link
FR (1) FR2888507B1 (en)
WO (1) WO2007006799A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3071726B1 (en) * 2017-09-29 2020-09-04 Univ Paris Sud TCTP PROTEIN INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
WO2020043716A1 (en) 2018-08-27 2020-03-05 Katholieke Universiteit Leuven Pharmacological targeting of de novo serine/glycine synthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
WO2007006799A1 (en) 2007-01-18
FR2888507A1 (en) 2007-01-19

Similar Documents

Publication Publication Date Title
ATE429585T1 (en) PIPING
CR10699A (en) WNT ANTAGONISTS AND ITS USE IN THE DIAGNOSIS AND TREATMENT OF WNT-USED DISORDERS
FR2907011B1 (en) USE OF CITRULLINE FOR THE TREATMENT OF DENUTRITION CONDITIONS
CY2200156T2 (en) WASTEWATER TREATMENT
ATE521365T1 (en) KININ ANTAGONISTS FOR THE TREATMENT OF BLADDER DISORDER
HK1146596A1 (en) Use of lingo-4 antagonists in the treatment of conditions involving demyelination lingo-4
FR2915102B1 (en) USE OF ANTI-CXCR4 ANTIBODY FOR THE TREATMENT OF CANCER
FR2899476B1 (en) ASSOCIATION OF MAZINDOL IN THE TREATMENT OF DEFICIT ATTENTION / HYPERACTIVITY
DK1611827T3 (en) Combined bath and shower
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
NO20043033L (en) Piping
FR2888507B1 (en) USE OF SERTRALINE IN COMBINATION WITH ALKALOID FOR THE TREATMENT OF CANCER
BRPI0714307A2 (en) USE OF TRIFLUORMETIL-SUBSTITUTED BENZAMIDS IN THE TREATMENT OF NEUROLOGICAL DISORDERS
FR2868312B1 (en) PATCH FOR THE TREATMENT OF LIP
FR2930156B1 (en) USE OF NONAPEPTIDE PAT IN THE TREATMENT OF AUTOIMMUNE DISEASES.
DK1773451T3 (en) Use of 7-t-butoxyiminomethylcamptothecin in the treatment of uterine neoplasms
NO20052429D0 (en) The contrast agents
GB0608797D0 (en) Novel agents and the use thereof
FR2867830B1 (en) LOCKABLE / UNLOCKABLE PIPING FITTING
ITMI20040989A1 (en) USE OF SULGLICOTIDE FOR THE TREATMENT OF MUCOSITES
FR2902321B1 (en) USE OF CURCUMIN FOR THE TREATMENT OF CANITIA
FR2918278B1 (en) USE OF OLEOCANTHAL IN THE TREATMENT OF SKIN INFLAMMATION.
ITMI20051576A1 (en) USE OF ISOTHIOCYANATES IN THE TREATMENT OF ACUTE LEUKEMIASES
EE200400064A (en) Use of ambroxol for the treatment of pharyngitis
FR2890402B1 (en) SEPTIC TANK

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100331